Anavex Life Sciences Corp (AVXL)

[falconer66a]

Blarcamesine Polytherapy

...possible applications of S1R agonist A2-73. There are over 200 cancers listed!!

I, too, read through that gigantic list of cancers in the new patent document. I saw one cancer of particular interest, Waldentrom’s macroglobulinemia (WM), a rare B-cell lymphoma. This was of particular interest because I have that disease. For five years, in my case, it’s been classified by my oncologist as “smoldering;” with low-grade symptoms not yet requiring any of the standard therapies. To help maintain this low-grade symptomatology, I take trans-resveratrol, an over the counter supplement which in Germany is the SOC (standard of care) initial treatment for WM. There is a reasonable likelihood that this will hold the disease in abeyance for many years. Or, the proteins of the disease will spike and I’ll need to take acalibrutinib, twice a day, orally, at a cost of many thousands of dollars a month (have health insurance).

Or, by the time my WM no longer smolders but fires up, perhaps blarcamesine (Anavex 2-73) will be available to treat my blood cancer. Hope so.

Especially, for another reason. With the long list of diseases in the new patent document that blarcamesine might be therapeutic for, I’ll take advantage of this polytherapeutic factor.

I have another morbidity that is not listed, but almost surely will respond favorably to blarcamesine: hereditary spastic paraplegia (HSP). I’ve had my genome analyzed, I definitely have a mild, slowly progressing form of this disease. Specifically, long neurons controlling various leg muscles lack sufficient gamma-aminobutyric acid (GABA). GABA is a neurotransmitter that inhibits over-activity of nerve impulses. Without sufficient GABA in their controlling nerves, the adductor muscles in my legs are tight, spastic, making walking difficult.

But, the girls in the Rett syndrome study showed that blarcamesine increased GABA production. I want that for my HSP. With it, I might be able, once again, to walk around without my walker.

When available, I’ll take blarcamesine to treat my WM, my leukemia; which at the same time may well treat my HSP. Two for the price one.

Two disease treatments at the same time: “polytherapy.” Watch. Once blarcamesine is widely prescribed it will be discovered that the drug treats not only the target disease, but at the same time other comorbidities are resolved. Eventually, blarcamesine will target not only the three central nervous system diseases presently in trial (Rett syndrome, Parkinson’s disease dementia, and Alzheimer’s disease) but an ever-widening catalog of diseases and conditions, which can be resolved by blarcamesine's propitious activation of the sigma-1 receptor protein.

At the same time, it will be discovered that blarcamesine is actually prophylactic; prevents the onset of a host of geriatric diseases and conditions.